XOMA has also completed enrollment in a larger Phase 2b trial of XOMA 052 in patients with Type 2 diabetes. Top line results from this dose-ranging trial, in which 420 patients were enrolled, are expected to be available in the first quarter of 2011. Patients on metformin therapy were randomized equally to one of four XOMA 052 dose groups or placebo for monthly treatments over six months. The primary outcome to be evaluated in this trial is mean change in HbA1c from baseline at the end of treatment. Additional diabetic outcomes as well as inflammatory and cardiovascular disease biomarkers will be evaluated. Further information is available at>

The Phase 2 trials follow a successful 98 patient Phase 1 program in Type 2 diabetes patients in which XOMA 052 was shown to be well-tolerated, demonstrated evidence of biological activity in diabetes measures and cardiovascular biomarkers, and had a half-life that may provide convenient dosing of once per month or less frequently.

"The completion of enrollment in the Phase 2 studies of XOMA 052 is an important step forward for XOMA in our efforts to develop a potentially disease-modifying medicine for Type 2 diabetes and other chronic indications," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "XOMA 052 is designed to treat the inflammatory cause of diabetes and other difficult diseases. It has the potential to provide patients an entirely new approach to controlling their disease."

Source :  XOMA